Krystal Biotech Inc (KRYS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.05B
Last updated: Nov 17, 2026 at 11:06 AM ET
Krystal Biotech Inc (KRYS) P/E Ratio & Valuation History
Krystal Biotech (KRYS) trades at 40.4x trailing earnings and 18.8x sales. Its P/B of 6.1x is above its 5-year median of 4.9x. Its forward P/E is 39.8x. The median P/E across 3 similar companies is 39.6x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 1.5% higher over the next year. Its free cash flow yield is 3.5%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 40.4x |
| Forward P/E | 39.8x |
| Price to sales | 18.8x |
| Price to book | 6.1x |
| EV/EBITDA | 35.7x |
| Price to FCF | 28.4x |
| EV/FCF | 27.0x |
| PEG | N/A |
| FCF yield | 3.5% |
Historical Medians
Against its 10-year medians, its P/B is 52.5% above 4.0x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 6.1x | 4.9x | 4.0x |
Valuation History
Over the 4 of the 9 year ends shown that have a P/S, its P/S ranged from 15.6x in 2024 to 274.5x in 2018.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $246.54 | 36.0x | 18.5x | 6.1x |
| 2024 | $156.66 | 46.1x | 15.6x | 4.9x |
| 2023 | $124.06 | N/A | 70.2x | 4.6x |
| 2022 | $79.22 | N/A | N/A | 3.9x |
| 2021 | $69.95 | N/A | N/A | 2.6x |
| 2020 | $60.00 | N/A | N/A | 4.1x |
| 2019 | $55.38 | N/A | N/A | 4.7x |
| 2018 | $20.78 | N/A | 274.5x | 2.5x |
| 2017 | $10.52 | N/A | N/A | 2.2x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About KRYS
What is KRYS's forward P/E ratio?
Krystal Biotech has a forward P/E ratio of 39.8x.
Is KRYS stock overvalued?
GNG's valuation label for KRYS is Undervalued. Its P/E of 40.4x compares with a median of 39.6x across 3 similar companies.
What is KRYS's price to sales ratio?
Krystal Biotech has a price to sales ratio of 18.8x.
KRYS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors